Clinical trials: Recurrent Cervical Cancer, open to volunteers
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Esophageal Squamous Cell Carcinoma (ESCC)
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
This observational study aims to understand the risk of cancer returning after surgery in people with esophageal squamous cell carcinoma, a type of cancer of the food pipe.
- Trial name
- NCT07822906
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Small Cell Carcinoma, Small Cell Carcinoma of Lung
Penfluridol for Relapsed/Refractory Small Cell Cancers
Penfluridol for Relapsed/Refractory Small-Cell Carcinoma of the Lung or Cervix: A Multicenter, Open-Label, Single-Arm Phase Ib/II Trial This study evaluates the safety and anti-tumor activity of oral penfluridol, a…
- Conditions
- Small Cell Carcinoma, Small Cell Carcinoma of Lung, Small Cell Lung Cancer ( SCLC ), Small Cell Cervical Carcinoma
- Trial name
- NCT07206563
- Testing
- Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma
Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer
This phase I trial is to find out the possible side effects of pembrolizumab and radiation therapy before and during surgery in treating patients with head and neck squamous cell cancer that remains despite treatment (persistent)…
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04754321
- Testing
- External Beam Radiation Therapy, Intraoperative Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating…
- Conditions
- Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT07783581
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Endometrial Cancer, Cervical Cancer
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Endometrial and Cervical Cancer. A Multicenter Study.
The role of small-volume lymph node disease (ITC and micro metastases) among patients with endometrial or cervical cancer submitted to sentinel node (SLN) procedure is not clearly defined.
- Conditions
- Endometrial Cancer, Cervical Cancer, Sentinel Lymph Node, Micrometastasis
- Trial name
- ITCMicroUtCa (NCT04403867)
- Testing
- Sentinel lymph node (SLN) biosy +/- lymphadenectomy
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Nasopharyngeal Carcinoma (NPC), Radiation Injuries
Pseudomembrane Removal for Post-RT Nasopharyngeal Necrosis
This study aims to evaluate the effectiveness and safety of endoscopic nasopharyngeal pseudomembrane removal in reducing radiation-induced nasopharyngeal necrosis in patients with recurrent nasopharyngeal carcinoma who have…
- Conditions
- Nasopharyngeal Carcinoma (NPC), Radiation Injuries, Necrosis
- Trial name
- EPoRN (NCT07552883)
- Testing
- Endoscopic Nasopharyngeal Pseudomembrane Removal
- Volunteers
- 40 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Cervical Cancer Screening
Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer
This is a prospective, single-center, observational cohort study that plans to enroll 100 women aged 18 years or older with histologically confirmed cervical cancer who are scheduled to receive radical surgery, radiotherapy, or…
- Trial name
- NCT07919431
- Testing
- Low-depth cfDNA fragmentomics testing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and…
- Trial name
- NCT05945875
- Testing
- Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cervical Cancer
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of Socazolimab combined with chemotherapy with or without bevacizumab as first-Line treatment in persistent, recurrent, or metastatic cervical cancer.
- Trial name
- NCT06459687
- Testing
- Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab
- Where
- 5 sites in China
- Volunteers
- 440 people
- Sponsor
- Lee's Pharmaceutical Limited
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
This phase II trial tests how well lovastatin and pembrolizumab work in treating patients with head and neck cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06636734
- Testing
- Biospecimen Collection, Computed Tomography, Lovastatin
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Emory University
Nasopharyngeal Carcinoma (NPC)
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of PD-1 monoclonal antibody combined with chemotherapy, followed by maintenance therapy with PD-1…
- Trial name
- NCT07783321
- Testing
- BL-B01D1, PD-1 monoclonal antibody, cisplatin
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants…
- Trial name
- OrigAMI-5 (NCT07276399)
- Testing
- Amivantamab, Pembrolizumab, Carboplatin
- Where
- 205 sites in United States, Australia and 20 more
- Volunteers
- 600 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer, Breast Cancer
Myeloprotection With Trilaciclib in Pan-cancer Population
The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT06297811
- Testing
- Trilaciclib Injection, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cervical Cancer, Cervical Cancer Metastatic
QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy
To explore the efficacy and safety of administrating QL1706 in patients with recurrent and/or metastatic cervical cancer who had developed resistance to prior PD-1/PD-L1 antibody therapies.
- Conditions
- Cervical Cancer, Cervical Cancer Metastatic, Cervical Cancer Recurrent, Cervical Adenocarcinoma
- Trial name
- NCT07141186
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer, Boron Neutron Capture Therapy
Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
This Phase II study, titled "A Phase II Study to Evaluate the Efficacy and Safety of Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Patients with Unresectable Recurrent Head and Neck Cancers," aims to assess the efficacy…
- Trial name
- NCT06952868
- Testing
- Drug: B10 L-BPA Injection
- Where
- 3 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- China Medical University Hospital
Nasopharyngeal Carcinoma (NPC)
TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial
Regarding the application value of capecitabine metronome chemotherapy's regulatory effect on the immune microenvironment in nasopharyngeal carcinoma, many studies in recent years have confirmed that metronome chemotherapy and…
- Trial name
- NCT06987123
- Testing
- Toripalimab, Capecitabine, salvage surgery
- Volunteers
- 62 people
- Sponsor
- Sun Yat-sen University
NPC, HNSCC
A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).
Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.
- Conditions
- NPC, HNSCC, Recurrence, Metastasis
- Trial name
- NCT06719479
- Testing
- IAE0972+ Methotrexate, IAE0972+Docetaxel, IAE0972+Gemcitabine
- Volunteers
- 60 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Oropharyngeal Cancer, Human Papilloma Virus
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic…
- Conditions
- Oropharyngeal Cancer, Human Papilloma Virus, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05582590
- Testing
- Fludarabine, Cyclophosphamide, NEXI-003 T cells
- Volunteers
- 36 people
- Sponsor
- NexImmune Inc.